作者
Michael Untch,CE Geyer,Aleix Prat,Priya Rastogi,Naoki Niikura,Elodie Mathias,LA McLean,Y Wang,Sibylle Loibl
摘要
Background Patients with residual invasive disease after NAT are at greater risk for disease recurrence or death than those with a pathological complete response. The antibody-drug conjugate (ADC) T-DM1 was recently approved as postneoadjuvant treatment for patients with residual invasive disease (in breast and/or axillary nodes) after NAT and anti-HER2-treatment. T-DXd is a potent HER2-targeted ADC that was recently approved following phase 2 evidence (Modi NEJM 2020) for the treatment of patients with HER2-positive, unresectable/metastatic BC with ≥2 prior anti-HER2─based regimens (US) or prior chemotherapy and being refractory to or intolerant of standard treatments (Japan). Methods DESTINY-Breast05 is a multicenter, open-label, randomized, phase 3 trial comparing efficacy and safety of T-DXd with T-DM1 in patients with HER2-positive (IHC 3+ or ISH+, centrally confirmed on pretreatment biopsy), invasive BC with residual invasive disease (breast and/or axillary lymph nodes) at presentation after NAT. Patients are eligible with either inoperable (cT4, N0-3, M0 or cT1-3, N2-3, M0) or operable BC (cT1-3, N0-1, M0) with axillary node-positive disease after NAT and anti-HER2-treatment. Approximately 1600 patients from 400 sites globally will be randomized (1:1) to T-DXd (5.4mg/kg) or T-DM1 (3.6mg/kg) intravenously once every 3 weeks for 14 cycles, stratified by operative status, hormone-receptor status, pathological nodal status, and anti-HER2-therapy. Primary endpoint is invasive disease-free survival, key secondary endpoint is disease-free survival. Other secondary endpoints are overall survival, distant recurrence-free interval, brain metastasis-free interval, safety. Pharmacokinetics of T-DXd, biomarkers, and health-related quality of life will be evaluated. Study start in Germany is planned for April 2021. Publication History Article published online: 01 June 2021 © 2021. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany